Journal article
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban
Abstract
BACKGROUND: Rivaroxaban is a novel oral anticoagulant indicated for prophylaxis against deep vein thrombosis and pulmonary embolism in patients undergoing total hip replacement (THR) or total knee replacement (TKR) surgery.
OBJECTIVE: To evaluate major bleeding (MB) in THR/TKR patients receiving post-operative rivaroxaban.
Authors
Kwong LM; Turpie AGG; Tamayo S; Peacock WF; Yuan Z; Sicignano N; Hopf KP; Patel MR
Journal
Current Medical Research and Opinion, Vol. 33, No. 9, pp. 1717–1723
Publisher
Taylor & Francis
Publication Date
September 2, 2017
DOI
10.1080/03007995.2017.1351935
ISSN
0300-7995